SOLID TUMOR

This study tests a custom-made vaccine designed to train the immune system to attack a person's specific cancer. It is for 136 adults with solid tumors that have not spread or have spread to other parts of the body. The vaccine is made from unique markers on each patient's tumor,…

This study was designed to test an experimental treatment called GT316, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced gynecological tumors. The goal was to see if the therapy was safe and could shrink tumors. However, the study was wit…

This early-phase study tests a new drug called LY3200882 in 223 people with solid tumors. The main goal is to check the drug's safety and find the best dose. Researchers will also see if the drug helps shrink tumors or slow cancer growth.

This early-phase study tests a new oral drug called inavolisib (GDC-0077) in people with advanced solid tumors or breast cancer that have a specific genetic change (PIK3CA mutation). The drug is given alone or combined with standard hormone therapies or targeted treatments. The m…

This study tests an experimental drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds the safest dose, and the second part checks i…

This early-phase study tests a new oral drug, ABSK121-NX, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 169 participants will take the drug in 28-day cycles, and…

This study tests a combination of two experimental drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the combo can shrink tumors. About 140 adults whose cancer has w…

This early-phase trial tests a new drug called BYON4228, alone or with pembrolizumab, in people with advanced solid tumors that have stopped responding to standard treatments. The study involves 7 participants and focuses on safety and whether the tumors shrink. It is not a cure …

This study tests the safety of the drug neratinib in children and teens with solid tumors, brain tumors, lymphoma, or leukemia that have returned or not responded to standard treatments. The goal is to find the right dose and see what side effects occur. 14 participants are enrol…

This early-phase study tests a new drug called GS-4528, given alone or with an immunotherapy drug, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 182 participants will take part…

This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…

This early-phase study tests a new treatment called BioTTT001, a modified virus designed to infect and kill cancer cells while boosting the immune system. It is for people with advanced solid tumors (like head and neck, colorectal, skin, or cervical cancer) who have not responded…

This early-stage trial tests a new treatment called BS006, a virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, f…

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have stopped responding to standard treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells by targeting two proteins (PD-1 and CTLA-4)…

This study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with a specific RET gene change. The main goal is to see if the drug can shrink tumors. Participants take the drug daily and are monitored for side …

This early-phase study tests a new drug called BL-M02D1 in 22 adults with advanced gastrointestinal or other solid tumors that cannot be cured or have no standard treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Part…

This study tests a personalized cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in 20 adults with solid tumors. The goal is to see if the combination is safe and helps control the disease better than immunotherapy alone. Participa…

This early-phase study tests a new liposomal formulation of the drug E7389 in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and evaluate side effects. The study includes patients with breast cancer, aden…

This study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or stop them from growi…

This early-phase study tests a combination of three drugs—bortezomib, gemcitabine, and doxorubicin—in people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the highest safe dose of the chemotherapy drugs when give…

This early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors like lung cancer, melanoma, head and neck cancer, and kidney cancer. The main goals are to check safety and find the right dose. About 552 people…

This early-stage study tests a new drug called ASP4396 in adults with advanced solid tumors that have a specific change in the KRAS gene (G12D mutation). The main goals are to check safety, find a good dose, and see how the body handles the drug. Participants receive the drug thr…

This early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). ALA helps cancer cells absorb more radiation, potentially killing them while sparing healthy tissue. The study involves 130 adults…

This study tests how well the drug sacituzumab govitecan works in people with advanced solid tumors that have not responded to other treatments. About 53 adults with certain types of esophageal or stomach cancer will receive the drug. The main goal is to see if tumors shrink or d…

This study was designed to test a new drug called IN10018 combined with chemotherapy and an immunotherapy for people with advanced solid tumors, specifically non-small cell lung cancer, who had already tried other treatments. The goal was to see if the combination could shrink tu…

This early-phase study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Participants re…

This study tests an experimental drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and can shrink tumors. About 315 adults whose cancer has not responded to standard treatments w…

This study tests a cancer-killing virus (VSV-IFNβ-NIS) given with an immunotherapy drug (pembrolizumab) in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The goal is to find the safest and most effective virus do…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This early-phase study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic) that have a specific genetic change called KRAS G12C. The main goal is to find the safest dose and check for side effects. About 44 adults who have tried other tre…

This early-stage trial tests a new treatment called CATCH T cells for people with certain solid tumors that have come back or not responded to standard care. The treatment involves taking a patient's own immune cells, adding new genes to help them recognize and attack cancer cell…

This study tests a combination of two drugs, SKB264 and pembrolizumab, in people with advanced cancers like cervical, bladder, ovarian, prostate, and endometrial cancer. The goal is to see if the combo can shrink tumors and control the disease. About 240 adults with specific soli…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and are still seeing benefits. Participants continue their treatment while researchers collect long-term safety informa…

This study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic features (dMMR or MSI-H). The drug aims to shrink tumors by blocking a DNA repair protein. The trial will check safety, side effects, and how well the drug work…

This study tests a drug called PRL3-zumab in 51 adults with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug can slow tumor growth or shrink tumors. Participants must have had 1 to 3 prior treatments. This is not a cure, but a…

This study tests the safety of combining the drug RP-3500 with palliative radiation therapy in people whose metastatic solid tumors have a specific change in the ATM gene. About 49 adults with advanced cancer will receive the combination to find the highest dose with few side eff…

This early-phase study tests a new two-drug combination taken by mouth for people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and understand side effects. Up to 35 participants will be enrolled.

This early-stage trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack a protein called HLA-G found on certain solid tumors. The study includes 31 adults with advanced solid tumors that have …

This early-stage study tests a new drug called IDE397 in adults with advanced solid tumors that have not responded to standard treatments. The drug targets a specific genetic change (MTAP deletion) found in some cancers. The main goals are to check the drug's safety, find the bes…

This early-phase study tests an experimental oral drug, HBI-2376, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific KRAS or EGFR gene mutations. The main goal is to find the safest dose and check for side effects. About 42 participan…

This study tests a new drug (C019199) combined with an immunotherapy (sintilimab) in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 155 adults with v…

This study tests whether benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The drug works by lowering eosinophil levels in the blood. About 51 adults with solid tumors or blood cancers who have moderate to severe skin reactions are…

This early-phase trial is testing whether the cholesterol drug atorvastatin can lower levels of a faulty protein (mutant p53) in people with solid tumors or relapsed acute myeloid leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery…

This study follows children and teens who have had cancer or a stem cell transplant to see how they do over many years. Researchers collect health information to understand long-term side effects of treatment. The goal is to find ways to reduce problems and improve quality of lif…

This study tests a new way to monitor proton therapy for solid tumors. By using a special PET scanner during treatment, doctors can see exactly where the proton beam goes in the body. The goal is to make sure the radiation hits the tumor accurately and avoids healthy tissue. Abou…

This study was designed to track how the immune system recovers after CAR-T cell therapy and whether a pneumonia vaccine (PCV-21) given six months later can work. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any partic…

This study tests whether special ultrasound scans can detect early signs that cancer immunotherapy is working. Researchers will measure blood flow changes in tumors after 3 weeks of treatment in 30 adults with solid tumors. The goal is to see if these changes can predict whether …

This study looks at whether older adults with cancer can use computer surveys to share their health information. Researchers will test two different computer methods to see which is easier and more reliable. The goal is to make it simpler for doctors to understand and help their …